The final, formatted version of the article will be published soon.
MINI REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1471409
This article is part of the Research Topic Immunological Precision Therapeutics: Integrating Multi-Omics Technologies and Comprehensive Approaches for Personalized Immune Intervention View all 9 articles
Cross-omics strategies and personalised options for lung cancer immunotherapy
Provisionally accepted
Yalan Yan
1
Siyi Sheng
1
Jiamin Li
1
Lanqian Su
1
Binbin Wang
2*
Jing-Han Zhang
3
Jiaan Lu
1
Huiyan Luo
4*
Ping Han
4*
Ke Xu
4*
Xiang Shen
5*
Shangke Huang
6*- 1 School of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China
- 2 Intensive Care Unit , Xichong People’s Hospital, Nanchong, China
- 3 Department of Anesthesiology, Southwest Medical University, Luzhou, China
- 4 Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China
- 5 Department of Respiratory and Critical care medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China
- 6 Deparment of Oncology, The Affiliated Hospital, Southwest Medical University, Luzhou, China
Lung cancer is one of the most common malignant tumours worldwide and its high mortality rate makes it a leading cause of cancer-related deaths. To address this daunting challenge, we need a comprehensive understanding of the pathogenesis and progression of lung cancer in order to adopt more effective therapeutic strategies. In this regard, integrating multi-omics data of the lung provides a highly promising avenue. Multi-omics approaches such as genomics, transcriptomics, proteomics, and metabolomics have become key tools in the study of lung cancer. The application of these methods not only helps to resolve the immunotherapeutic mechanisms of lung cancer, but also provides a theoretical basis for the development of personalised treatment plans. By integrating multi-omics, we have gained a more comprehensive understanding of the process of lung cancer development and progression, and discovered potential immunotherapy targets. This review summarises the studies on multi-omics and immunology in lung cancer, and explores the application of these studies in early diagnosis, treatment selection and prognostic assessment of lung cancer, with the aim of providing more personalised and effective treatment options for lung cancer patients.
Keywords: lung cancer, Immunotherapy, precision medicine, multi-omics, individualised therapy, immune checkpoints
Received: 27 Jul 2024; Accepted: 30 Aug 2024.
Copyright: © 2024 Yan, Sheng, Li, Su, Wang, Zhang, Lu, Luo, Han, Xu, Shen and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Binbin Wang, Intensive Care Unit , Xichong People’s Hospital, Nanchong, China
Huiyan Luo, Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China
Ping Han, Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China
Ke Xu, Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China
Xiang Shen, Department of Respiratory and Critical care medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China
Shangke Huang, Deparment of Oncology, The Affiliated Hospital, Southwest Medical University, Luzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.